BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

CODA Genomics, Inc. Closes Investment Led By Tech Coast Angels


10/19/2005 5:13:18 PM

IRVINE, Calif., Oct. 5 /PRNewswire/ -- CODA Genomics, Inc. (CODA), a synthetic biology and protein expression company, announced today that it has closed a Series A funding of over $800,000 from the Tech Coast Angels (TCA). Jay S. Kunin, Ph.D. and Robert Engler, MD have joined the CODA Board of Directors as investor representatives. Dr. Kunin is an independent consultant, investor, and expert in medical and pharmaceutical software. He is also a Director of several companies, TCA San Diego Network, and the Life Science Information Technology Global Institute. Dr. Engler was a Professor of Medicine, UCSD, in Cardiology from 1975-2001. He has authored 19 book chapters and over 80 scientific publications, and was a founder of Gensia, Collateral Therapeutics, and the Veterans Medical Research Foundation. He currently is a cardiovascular consultant, angel investor and Director of a number of private, public, and non-profit corporations.

Dr. Robert Molinari, CEO of CODA comments, "We are delighted to have TCA invest in CODA. With synthetic biology becoming an important investment area, TCA, with many experienced life science entrepreneurs as members, is ideally suited to lead this investment.

TCA, the largest U.S. angel investor network, provides funding and guidance to most early-stage companies in Southern California. Since 1997, TCA members have invested $58 million in 91 companies and have leveraged these investments into more than $552 million in venture co-investment for TCA portfolio companies. TCA offers not only capital, but also mentoring, recruiting help, and access to investors and partners. TCA has more than 270 members in its four networks in Los Angeles, Orange County, San Diego and Westlake/Santa Barbara.

CODA was started in 2004 to commercialize DNA assembly and protein expression work, developed under an Information Technology Research award from the National Science Foundation, from the laboratories of Drs. Richard Lathrop and G. Wesley Hatfield at the University of California, Irvine. In addition to DNA thermodynamics, CODA optimizes codon usage preferences AND codon pair-wise combinations to generate high levels of the proper protein constructs. CODA offers CODExpress gene kits and assembled genes that are guaranteed to express specific proteins, and collaborative protein drug optimization projects. CODA's patented Translation Engineering creates DNA constructs that enable directed research on protein structure/function properties such as solubility, excretion, and folding.

CODA Genomics, Inc.

CONTACT: Dr. Robert Molinari, CEO of CODA Genomics, Inc, +1-650-917-9256,mole@codagenomics.com



Read at BioSpace.com

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES